FHTX
NASDAQ
$5.16
Foghorn Therapeutics Inc (FHTX)
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $11.44 (+121.71%)
Market Cap
$320M
Revenue 5Y CAGR
+108.52%
Free Cash Flow Yield
-27.32%
Beta (5Y)
1.79
Price Chart
Valuation
Market Cap$320M
P/S11.34
P/B2005.35
Profitability
Total Revenue (TTM)$28M
Gross Profit (TTM)-$54M
EBITDA-$82M
Profit Margin-266.9%
Operating Margin-660%
EPS-$1.32
Financial Health
Free Cash Flow Yield-27.32%
Growth & Risk
Revenue 5Y CAGR+108.52%
FCF 5Y CAGR+7.59%
Beta (5Y)1.79
Sharpe Ratio0.11